Dyne Therapeutics annual free cash flow
2019
2020
2021
2022
2023
2024
2025
Dyne Therapeutics Free Cash Flow (FCF) History (DYN)
Dyne Therapeutics reported −$405.1M in free cash flow for fiscal 2025, a decrease of $110.4M from the previous fiscal year.
View full Dyne Therapeutics company overviewDyne Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$405.1M | −$110.4M | — | — |
| 2024 | 2024-12-31 | −$294.7M | −$105.9M | — | — |
| 2023 | 2023-12-31 | −$188.9M | −$32.2M | — | — |
| 2022 | 2022-12-31 | −$156.7M | −$33.5M | — | — |
| 2021 | 2021-12-31 | −$123.2M | −$75.5M | — | — |
| 2020 | 2020-12-31 | −$47.7M | −$34.2M | — | — |
| 2019 | 2019-12-31 | −$13.5M | — | — | — |
Dyne Therapeutics quarterly free cash flow
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$131.8M | −$37.0M | — | — |
| Q1 2026 | 2026-03-31 | −$145.1M | −$38.3M | — | — |
| Q4 2025 | 2025-12-31 | −$112.3M | −$26.9M | — | — |
| Q3 2025 | 2025-09-30 | −$91.2M | −$16.3M | — | — |
| Q2 2025 | 2025-06-30 | −$94.8M | −$39.0M | — | — |
| Q1 2025 | 2025-03-31 | −$106.9M | −$28.1M | — | — |
| Q4 2024 | 2024-12-31 | −$85.4M | −$50.3M | — | — |
| Q3 2024 | 2024-09-30 | −$74.9M | −$24.1M | — | — |
| Q2 2024 | 2024-06-30 | −$55.7M | $167,000 | — | — |
| Q1 2024 | 2024-03-31 | −$78.7M | −$31.6M | — | — |
| Q4 2023 | 2023-12-31 | −$35.1M | −$5.4M | — | — |
| Q3 2023 | 2023-09-30 | −$50.8M | −$7.1M | — | — |
| Q2 2023 | 2023-06-30 | −$55.9M | −$24.7M | — | — |
| Q1 2023 | 2023-03-31 | −$47.1M | $5.0M | — | — |
| Q4 2022 | 2022-12-31 | −$29.7M | $347,000 | — | — |
| Q3 2022 | 2022-09-30 | −$43.7M | −$15.9M | — | — |
| Q2 2022 | 2022-06-30 | −$31.2M | $15.7M | — | — |
| Q1 2022 | 2022-03-31 | −$52.1M | −$33.7M | — | — |
| Q4 2021 | 2021-12-31 | −$30.1M | −$9.3M | — | — |
| Q3 2021 | 2021-09-30 | −$27.8M | −$15.8M | — | — |
| Q2 2021 | 2021-06-30 | −$46.9M | −$39.5M | — | — |
| Q1 2021 | 2021-03-31 | −$18.4M | −$10.9M | — | — |
| Q4 2020 | 2020-12-31 | −$20.8M | — | — | — |
| Q3 2020 | 2020-09-30 | −$12.0M | — | — | — |
| Q2 2020 | 2020-06-30 | −$7.4M | — | — | — |
| Q1 2020 | 2020-03-31 | −$7.5M | — | — | — |
Dyne Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$47.7M to −$405.1M, a net decrease of $357.5M. Dyne Therapeutics's latest reported quarter, Q2 2026, generated −$131.8M in free cash flow, a decrease of $37.0M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Dyne Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...
